Frequent urination

Results: 38



#Item
11Catheter-Associated Urinary Tract Infection (CAUTI) in Patients >12 Months of Age, 2015 Urine culture with no more than two species of organisms, with at least one organism being a bacteria of >105 CFU/ml  No

Catheter-Associated Urinary Tract Infection (CAUTI) in Patients >12 Months of Age, 2015 Urine culture with no more than two species of organisms, with at least one organism being a bacteria of >105 CFU/ml No

Add to Reading List

Source URL: health.utah.gov

Language: English - Date: 2014-12-18 16:54:06
12Astellas Obtained Approval for Vesicare OD in Japan Tokyo, October 27, [removed]Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced that it obtained the approval of ma

Astellas Obtained Approval for Vesicare OD in Japan Tokyo, October 27, [removed]Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced that it obtained the approval of ma

Add to Reading List

Source URL: www.astellas.com

Language: English - Date: 2010-10-26 22:39:57
13June 1, 2006 Astellas Launches “Vesicare®” for the treatment of Overactive Bladder in Japan Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Toichi Takenaka) today announced that Vesicar

June 1, 2006 Astellas Launches “Vesicare®” for the treatment of Overactive Bladder in Japan Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Toichi Takenaka) today announced that Vesicar

Add to Reading List

Source URL: www.astellas.com

Language: English - Date: 2008-09-19 00:56:17
14June 18, 2010  Application for Mirabegron (YM178), a Treatment for OAB, in Japan Tokyo, Japan, June 18, [removed]Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced th

June 18, 2010 Application for Mirabegron (YM178), a Treatment for OAB, in Japan Tokyo, Japan, June 18, [removed]Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced th

Add to Reading List

Source URL: www.astellas.com

Language: English - Date: 2010-06-17 22:05:31
15Recovery After Stroke: Bladder & Bowel Function Problems with bladder and bowel function are common but

Recovery After Stroke: Bladder & Bowel Function Problems with bladder and bowel function are common but

Add to Reading List

Source URL: www.stroke.org

Language: English - Date: 1970-01-01 04:13:24
16August 29, 2011  Astellas Pharma Inc.: Announcement of Regulatory Submission for Mirabegron (YM178), a Treatment for Overactive Bladder, in U.S. and Europe Tokyo, August 29, [removed]Astellas Pharma Inc. (Tokyo:4503, “As

August 29, 2011 Astellas Pharma Inc.: Announcement of Regulatory Submission for Mirabegron (YM178), a Treatment for Overactive Bladder, in U.S. and Europe Tokyo, August 29, [removed]Astellas Pharma Inc. (Tokyo:4503, “As

Add to Reading List

Source URL: www.astellas.com

Language: English - Date: 2011-08-26 02:56:51
17September 15, 2011  Astellas Pharma Inc. Launches Betanis® Tablet, a Treatment for OAB, in Japan -Provides a New Option for Patients with OAB Tokyo, Japan, September 15, [removed]Astellas Pharma Inc. (Tokyo:4503,“Astell

September 15, 2011 Astellas Pharma Inc. Launches Betanis® Tablet, a Treatment for OAB, in Japan -Provides a New Option for Patients with OAB Tokyo, Japan, September 15, [removed]Astellas Pharma Inc. (Tokyo:4503,“Astell

Add to Reading List

Source URL: www.astellas.com

Language: English - Date: 2011-09-14 05:44:33
18MYRBETRIQ™ (mirabegron), Overactive Bladder Treatment from Astellas, Now Available Through U.S. Pharmacies NORTHBROOK, Ill., Oct. 22, 2012 – Astellas Pharma US, Inc. (“Astellas”), a U.S. subsidiary of Tokyobased

MYRBETRIQ™ (mirabegron), Overactive Bladder Treatment from Astellas, Now Available Through U.S. Pharmacies NORTHBROOK, Ill., Oct. 22, 2012 – Astellas Pharma US, Inc. (“Astellas”), a U.S. subsidiary of Tokyobased

Add to Reading List

Source URL: www.astellas.com

Language: English - Date: 2012-10-22 19:12:22
19Side effects of Prostate Cancer Treatment Type of Treatment Possible Late Complications (Months-Years after Treatment)

Side effects of Prostate Cancer Treatment Type of Treatment Possible Late Complications (Months-Years after Treatment)

Add to Reading List

Source URL: www.rtanswers.org

Language: English - Date: 2014-09-09 09:26:07
20Symptoms (LUTS) in Males: Benign Prostate Hyperplasia…BPH

Symptoms (LUTS) in Males: Benign Prostate Hyperplasia…BPH

Add to Reading List

Source URL: bayregionalcancer.com

Language: English - Date: 2012-07-27 09:40:43